[
    "of metalloproteinase; Metal; The oncogene inhibitor; Genetic transcription or RNA translation (translation) or protein expression\ue003 inhibitor; The rare earth element complex; And light chemotherapeutics.\n      </p>Preferred compound comprises micromolecule tyrosine kinase or serine/threonine kinase inhibitor; With nucleic acid interaction, and be categorized as the compound of alkylating agent class or anthracycline; Antimetabolite; The DNA transcripting enzyme inhibitor, as the inhibitor of topoisomerase I or topoisomerase II; The tubulin binding medicine; Antimitotic agent; The antibody of targeting somatomedin or its receptor; And combine with the cancerous cell surface molecular, or the antibody combined with the part of these surface moleculars, can be its hydrate and/or solvate forms, and the form of its optional independent optical isomer, independent enantiomeric mixture or racemate.</p>In another preferred embodiment, the present invention relates to drug regimen, wherein other chemotherapeutics, or natural existence, semi-synthetic or synthetic therapeutic agent\n        2be selected from: the small molecular antagonists of vegf receptor, as PTK787 (vatalanib) (PTK-787/ZK222584), SU-5416, SU-6668, SU-11248, SU-14813, AZD-6474, AZD-2171, CP-547632, CEP-7055, AG-013736, IM-842 or GW-786034, the EGFR/HER2 dual antagonist, as Gefitinib (gefitinib), Erlotinib (erlotinib), CI-1033 or GW-2016, the EGFR antagonist, as Iressa (iressa) (ZD-1839), Erlotinib (tarceva) (OSI-774), PKI-166, EKB-569, HKI-272 or Trastuzumab (herceptin), the mitogen-activated protein kinase antagonist, as BAY-43-9006 or BAY-57-9006, quinazoline derivant, 4-fluorophenyl as chloro-as 4-[(3-) amino]-6-{[4-(N, the N-dimethylamino)-1-oxo-2-butene-1-yl] amino }-7-((S)-oxolane-3-base oxygen base base)-quinazoline or fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-{[4-(high morpholine-4-yl)-1-oxo-2-butene-1-yl] amino }-7-[(S)-oxolane-3-yl) the oxygen base]-quinazoline, or its officinal salt, the protein kinase receptor antagonist that does not belong to the synthesized micromolecule class, for example atrasentan (atrasentan), Rituximab (rituximab), Cetuximab (cetuximab), Arastin (Avastin)\n        <sup>TM</sup>[bevacizumab (bevacizumab)], IMC-1C11, Erbitux (erbitux) (C-225), DC-101, EMD-72000, Wei Taxin (vitaxin), Imatinib (imatinib), protein tyrosine kinase inhibitor, it is fusion, as VEGFtrap, alkylating agent or platinum compounds, as melphalan (melphalan), endoxan (cyclophosphamide), oxynitride phosphor heterocycle hexene (oxazaphosphorine), cis-platinum (cisplatin), carboplatin (carboplatin), oxaliplatin (oxaliplatin), Satraplatin (satraplatin), four platinum (tetraplatin), iproplatin (iproplatin), mitomycin (mitomycin), streptozotocin (streptozocin), BCNU (carmustine) (BCNU), lomustine (lomustine) (CCNU), busulfan (busulfan), ifosfamide (ifosfamide), streptozotocin (streptozocin), thiophene is for sending (thiotepa), Chlorambucil (chlorambucil), mustargen, as mechlorethamin",
    "tal protease inhibitors, as TIMP-1 or TIMP-2, zinc, the oncogene inhibitor, as P53 and Rb, the rare earth element compound, as group of the lanthanides heterocycle compound, the light chemotherapeutics, as PUVA, the inhibitor of transcription factor complex ESX/DRIP130/Sur-2, the agent of HER-2 expression inhibiting, as heat shock protein HSP90 conditioning agent geldanamycin (geldanamycin), and derivative 17-AAG (17-allylaminogeldanamycin) or 17-AAG, or be selected from IM-842, tetrathiomolybdate (tetrathiomolybdate), squalamine (squalamine), his spit of fland (combrestatin) A4 of crith, TNP-470, Marimastat (marimastat), Neovastat (neovastat), Bicalutamide (bicalutamide), abarelix (abarelix), Ao Ruige monoclonal antibody (oregovomab), mitumomab (mitumomab), TLK-286, alemtuzumab (alemtuzumab), ibritumomab tiuxetan (ibritumomab), Temozolomide (temozolomide), denileukin-2 (denileukin diftitox), Aldesleukin (aldesleukin), Dacarbazine (dacarbazine), floxuridine (floxuridine), plicamycin (plicamycin), mitotane (mitotane), Amedel (pipobroman), plicamycin (plicamycin), the therapeutic agent of TAM (tamoxifen) and Testolactone (testolactone).\n      </p>Preferred compound comprises the vegf receptor small molecular antagonists, as PTK787 (vatalanib) (PTK-787/ZK222584), SU-5416, SU-6668, SU-11248, SU-14813, AZD-6474, EGFR/HER2 antagonist, as CI-1033 or GW-2016; The EGFR antagonist, as Iressa (iressa) [gefitinib (gefitineb) ZD-1839], Erlotinib (tarceva) [erlotinib (erlotinib) OSI-774], PKI-166, EKB-569, HKI-272 or Trastuzumab (herceptin); Mitogen activated protein kinase antagonist, as BAY-43-9006 or BAY-57-9006; Atrasentan (atrasentan), Rituximab (rituximab), Cetuximab (cetuximab), Arastin (Avastin)\n        <sup>tM</sup>[bevacizumab (bevacizumab)], IMC-1C11, Erbitux (erbitux) (C-225), DC-101, EMD-72000, Wei Taxin (vitaxin), imatinib (imatinib); Alkylating agent or platinum compounds, as melphalan (melphalan), cyclophosphamide (cyclophosphamide), cisplatin (cisplatin), carboplatin (carboplatin), oxaliplatin (oxaliplatin), Satraplatin (satraplatin); Daunorubicin (daunorubicin), doxorubicin (doxorubicin) [amycin (adriamycin)], doxorubicin (doxorubicin) liposome [Doxil (doxil)], epirubicin (epirubicin), idarubicin (idarubicin); The analog of pyrimidine or purine or antagonist, or the ribonucleoside diphosphate reductase inhibitor, as cytosine arabinoside (cytarabine), 5-fluorouracil (5-FU), pemetrexed (pemetrexed), ftorafur (tegafur)/uracil (uracil), gemcitabine (gemcitabine), capecitabine (capecitabine), mercaptopurine (mercaptopurine), methotrexate (methotrexate); Anticarcinogen, as paclitaxel (paclitaxel) (taxol (taxol)) or Docetaxel (docetaxea); Vinca alkaloids, as nvelbine (navelbine), vinblastine (vinblastin), vincristine (vincristin), vindesine (vindesine) or vinorelbine (vinorelbine); The resisting mitosis peptide, as Duo Lasitating (dolastatin); Epipodophyllotoxin or podophyllotoxin derivative, as etoposide (etoposide) or teniposide (teniposide); NSAI",
    "ne (propamidine) or stilbamidine (stibamidine), antramycin (anthramycin), aziridine (aziridine), the nitroso ureas or derivatives thereof, the analog of pyrimidine or purine or antagonist, or the ribonucleoside diphosphate reductase inhibitor, as cytosine arabinoside (cytarabine), 5-fluorouracil (5-FU), uracil mustard (uracil mustard), fludarabine (fludarabine), gemcitabine (gemcitabine), capecitabine (capecitabine), mercaptopurine (mercaptopurine), cladribine (cladribine), thioguanine (thioguanine), methotrexate (methotrexate), pentostatin (pentostatin), hydroxyurea (hydroxyurea) or folic acid, the acridine or derivatives thereof, rifamycin (rifamycin), D actinomycin D (actinomycin), methacycline (adramycin), camptothecine (camptothecin), as Irinotecan (irinotecan) (camptosar) or hycamtin (topotecan), amsacrine or its analog, three ring carboxylic acid amides, histone deacetylase inhibitors, as SAHA, MD-275, trichostatin (trichostatin) A, CBHA, LAQ824 or valproic acid, proteasome inhibitor, as bortezomib (bortezomib), the small molecular antagonists of vegf receptor, as PTK787 (vatalanib) (PTK-787/ZK222584), SU-5416, SU-6668, SU-11248, SU-14813, AZD-6474, AZD-2171, CP-547632, CEP-7055, AG-013736, IM-842 or GW-786034, the mitogen-activated protein kinase antagonist, as BAY-43-9006 or BAY-57-9006, the EGFR/HER2 dual antagonist, as gefitinib (gefitinib), erlotinib (erlotinib), CI-1033 or GW-2016, the EGFR antagonist, as Iressa (iressa) (ZD-1839), Erlotinib (tarceva) (OSI-774), PKI-166, EKB-569, HKI-272 or Trastuzumab (herceptin), quinazoline derivant, 4-fluorophenyl as chloro-as 4-[(3-) amino]-6-{[4-(N, the N-dimethylamino)-1-oxo-2-butylene-1-yl] amino }-7-((S)-oxolane-3-base oxygen base)-quinazoline or fluoro-phenyl of the chloro-4-of 4-[(3-) amino]-6-{[4-(high morpholine-4-yl)-1-oxo-2-butylene-1-yl] amino }-7-[(S)-oxolane-3-yl) the oxygen base]-quinazoline, or its officinal salt, the inhibitor of transcription factor complex ESX/DRIP130/Sur-2, the HER-2 expression inhibitor, as heat shock protein HSP90 regulator geldanamycin (geldanamycin), and derivant 17-AAG (17-allylaminogeldanamycin) or 17-AAG, the protein kinase receptor antagonist that does not belong to the synthesized micromolecule class, as atrasentan (atrasentan), Rituximab (rituximab), Cetuximab (cetuximab), Arastin (Avastin\n        <sup>tM</sup>) [bevacizumab (bevacizumab)], IMC-1C11, Erbitux (erbitux) (C-225), DC-101, EMD-72000, Wei Taxin (vitaxin), imatinib (imatinib), and the antibody of target cancer cell surface molecular, monoclonal antibody as sharp as Ah pool (apolizumab) or 1D09C3.\n      </p>Preferred compound comprises the micromolecule receptor antagonist, as PTK787 (vatalanib), SU-11248 or AZD-6474; EGFR or HER2 antagonist, as gefitinib (gefitinib), erlotinib (erlotinib), CI-1033 or Trastuzumab (herceptin); Antibody, as bevacizumab (bevacizumab), Cetuximab (cetuximab), Rituximab (rituximab); The DNA alkylating agent, as cisplatin (cisplatin), oxaliplatin (oxaliplatin) or c"
]